Reblozyl (luspatercept)

Reblozyl is called Rojuzda internationally.  Our Rojuzda is manufactured in the United States and shipped by courier from India.

Information about Reblozyl (Luspatercept)

Reblozyl is a prescription medication that contains luspatercept, a protein-based drug designed to treat anemia associated with certain blood disorders. It works by enhancing the maturation of red blood cells and increasing hemoglobin production. Luspatercept is commonly used in patients with beta-thalassemia or myelodysplastic syndromes (MDS) who need regular blood transfusions to manage their anemia. 

Product Highlights

• Reblozyl is approved for the treatment of anemia in patients with beta-thalassemia who need regular red blood cell transfusions. Beta-thalassemia is a genetic blood disorder that results in decreased production of hemoglobin. 
• It is used in patients with MDS, particularly those with anemia who require frequent blood transfusions. MDS is a group of bone marrow disorders where the body is unable to produce enough healthy blood cells. 

Key Ingredient

• Luspatercept

Key Benefits

• Reblozyl has been shown to decrease the need for blood transfusions in patients with beta-thalassemia and MDS, improving quality of life and reducing complications related to frequent transfusions.
• By promoting the production and maturation of red blood cells, Reblozyl helps increase hemoglobin levels, alleviating symptoms of anemia like fatigue and weakness.
• It provides a long-term treatment option for managing anemia in patients with chronic conditions like beta-thalassemia and MDS.
• Reblozyl is given by injection under the skin, which is typically easier for patients compared to other forms of treatment like intravenous infusions.

Direction of Use

• Reblozyl is typically administered as a subcutaneous injection (under the skin) every 3 weeks. The exact dose and frequency may vary based on the patient’s specific condition and response to treatment.
• Reblozyl should be administered by a healthcare professional or trained caregiver. The injection site should be rotated to minimize irritation.
• Regular blood tests are required to monitor hemoglobin levels and assess the response to treatment. Your healthcare provider may adjust the dose based on your response.

Safety Concerns

• Reblozyl can increase the risk of blood clots, including deep vein thrombosis (DVT) or pulmonary embolism (PE). Close monitoring for signs of blood clots is important.
• In patients who require frequent blood transfusions, iron overload can occur, which may lead to organ damage. It is important to monitor iron levels and use iron chelation therapy if needed.
• While Reblozyl stimulates red blood cell production, it may also affect other blood cell lines, leading to issues like thrombocytosis (high platelet count) or neutropenia (low white blood cell count). Frequent monitoring of blood cell counts is crucial. 
• Allergic reactions to Reblozyl, including skin rashes, itching, and anaphylaxis, can occur. Urgent medical attention is needed if signs of a severe allergic reaction occur. 
• Reblozyl is not recommended during pregnancy due to potential harm to the fetus. Reliable contraception should be used during treatment and for at least 6 months following the last dose. 

Avoid Reblozyl (Luspatercept) If

• You have an allergy to luspatercept or any of the ingredients in the medication. 
• You have a history of blood clots (DVT, PE) or other thromboembolic events, as Reblozyl may increase the risk of these complications.
• You are pregnant or planning to become pregnant, as the effects of Reblozyl on fetal development are not well-studied.
• You have severe liver or kidney disease, as Reblozyl has not been fully evaluated in these patients, and caution is advised.
• You have uncontrolled hypertension, as high blood pressure may increase the risk of complications when using Reblozyl.
• You are breastfeeding, as it is not known if luspatercept passes into breast milk, and the potential risks to a nursing infant are unclear.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.